Conexxence Purple Book BLA 761398
- BLA number
- 761398
- Proprietary names
- Conexxence, Bomyntra
- Proper names
- denosumab-bnht
- Applicant
- Fresenius Kabi USA, LLC
- Center
- CDER
- First observed release
- 2025-06-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Conexxence | denosumab-bnht | 351(k) Interchangeable | 60MG/ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2025-03-25 | |
| 002 | Bomyntra | denosumab-bnht | 351(k) Interchangeable | 120MG/1.7ML (70MG/ML) | Injection | Subcutaneous | Single-Dose Vial | Rx | Licensed | 2025-03-25 | |
| 003 | Bomyntra | denosumab-bnht | 351(k) Interchangeable | 120MG/1.7ML (70MG/ML) | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2025-03-25 | |
Reference Biological Product#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 125320 | Prolia | denosumab | 351(a) | Rx | 2026-06-01 |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2025-11-01 | U | 001 | Conexxence | 351(k) Interchangeable | Rx | Fresenius Kabi USA, LLC |
| 2025-11-01 | U | 002 | Bomyntra | 351(k) Interchangeable | Rx | Fresenius Kabi USA, LLC |
| 2025-11-01 | U | 003 | Bomyntra | 351(k) Interchangeable | Rx | Fresenius Kabi USA, LLC |
| 2025-06-01 | N | 001 | Conexxence | 351(k) Biosimilar | Rx | Fresenius Kabi USA, LLC |
| 2025-06-01 | N | 002 | Bomyntra | 351(k) Biosimilar | Rx | Fresenius Kabi USA, LLC |
| 2025-06-01 | N | 003 | Bomyntra | 351(k) Biosimilar | Rx | Fresenius Kabi USA, LLC |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2025-11-01 | 001 | Conexxence | 351(k) Interchangeable | Rx | Licensed | 2025-03-25 |
| 2025-11-01 | 002 | Bomyntra | 351(k) Interchangeable | Rx | Licensed | 2025-03-25 |
| 2025-11-01 | 003 | Bomyntra | 351(k) Interchangeable | Rx | Licensed | 2025-03-25 |
| 2025-06-01 | 001 | Conexxence | 351(k) Biosimilar | Rx | Licensed | 2025-03-25 |
| 2025-06-01 | 002 | Bomyntra | 351(k) Biosimilar | Rx | Licensed | 2025-03-25 |
| 2025-06-01 | 003 | Bomyntra | 351(k) Biosimilar | Rx | Licensed | 2025-03-25 |